Table 3 PD assessment of peripheral blood cytokines.

From: Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma

Serum cytokine

PD (N = 2) serum levels (ng/ml)

PR/SD (N = 8) serum levels (ng/ml)

P value

IL17A

176.38

−15.89

0.005

IL2

262.18

−2.95

0.006

IL21

1454.21

51.3

0.001

PDGFB

257.87

−42.7

0.033

TRAIL

1006.81

192.2

0.035

  1. Changes between baseline and on-treatment levels of soluble immune mediators assessed by LUMINEX assay in patients with and without clinical benefit from the study treatment. Note that the majority of samples were excluded from analysis due to high coefficient of variation between replicate samples and or low level below the limit of quantitation of the LUMINEX assay.
Back to article page